Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

121. Guidance for antenatal screening and ultrasound in pregnancy in the evolving coronavirus (COVID-19) pandemic

Guidance for antenatal screening and ultrasound in pregnancy in the evolving coronavirus (COVID-19) pandemic 1 Information for healthcare professionals Version 1: Published Monday 23 March 2020 Guidance for antenatal screening and ultrasound in pregnancy in the evolving coronavirus (COVID-19) pandemic2 Authors Matthew Jolly, NHS England & NHS Improvement Myles T aylor, BMFMS Jane Fisher, ARC Nadia Permalloo, PHE Annette McHugh, PHE Christoph Lees, Imperial College/ISUOG Pranav Pandya, UCLH/PHE (...) Eddie Morris, RCOG Jo Mountfield , RCOG Tim Draycott, RCOG Pat O’Brien, RCOG Ranee Thakar, RCOG Sue Ward, RCOG Jennifer Jardine, RCOG Sophie Relph, RCOG Gemma Goodyear, RCOG3 1. Introduction There are 3 antenatal screening programmes: • Sickle cell and thalassaemia (SCT) • Infectious disease in pregnancy screening (IDPS) • Fetal anomaly screening (FASP) Pregnant women with existing type 1 and type 2 diabetes should also be offered eye screening at, or soon after, their first antenatal visit

2020 Royal College of Obstetricians and Gynaecologists

122. Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 Full Text available with Trip Pro

Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19 April 7, 2020 Kile Green 1 , Sara (...) and G (IgM and IgG). IgM is the largest immunoglobulin, and is the first to appear after initial exposure to an antigen. IgG is the most common antibody found in the body, which will appear later but will be generated in abundance. These tests can determine whether a patient has previously been infected with coronavirus, as they will stay positive after active infection has gone. Currently, serological testing is not routinely offered as part of the screening or diagnosis of COVID-19

2020 Oxford COVID-19 Evidence Service

123. Covid-19: Infrared Temperature Screening to Identify Potentially Infected Staff or Visitors Presenting to Healthcare Facilities during Infectious Disease Outbreaks

Covid-19: Infrared Temperature Screening to Identify Potentially Infected Staff or Visitors Presenting to Healthcare Facilities during Infectious Disease Outbreaks CLINICAL EVIDENCE ASSESSMENT Share Your Feedback on how this report answered your question by visiting ly.ecri.org/rate © March 2020 ECRI Infrared Temperature Screening to Identify Potentially Infected Staff or Visitors Presenting to Healthcare Facilities during Infectious Disease Outbreaks Temperature monitoring during infectious (...) disease outbreaks has become commonplace, and various monitoring approaches have been taken at public entry points such as health systems and airports. A common method has been the use of external infrared (IR) temperature screening devices with or without questionnaires for visitors and staff entering healthcare facilities to identify those who may have potentially infectious disease and prevent their entry into the facility. This report focuses on the accuracy of these systems for identifying

2020 Covid-19 Ad hoc papers

124. Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations. (Abstract)

Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations. Hepatitis C virus (HCV) disproportionately affects disadvantaged communities.To examine processes and outcomes of Screen, Treat, Or Prevent Hepatocellular Carcinoma (STOP HCC), a multicomponent intervention for HCV screening and care in safety-net primary care practices.Mixed-methods retrospective analysis.5 federally qualified health centers (FQHCs) and 1 family (...) with chronic HCV in 4 practices, quantitative data also enabled assessment of HCV staging, specialist teleconsultation, direct-acting antiviral (DAA) treatment, and sustained virologic response (SVR). Implementation fidelity and adaptation were assessed qualitatively.Anti-HCV screening was done in 13 334 of 27 700 baby boomers (48.1%, varying by practice from 19.8% to 71.3%). Of 695 anti-HCV-positive patients, HCV RNA was tested in 520 (74.8%; 48.9% to 92.9% by practice), and 349 persons (2.6% of those

2019 Annals of Internal Medicine

125. Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. An abdominal aortic aneurysm (AAA) is typically defined as aortic enlargement with a diameter of 3.0 cm or larger. The prevalence of AAA has declined over the past 2 decades among screened men 65 years or older in various European countries. The current prevalence of AAA in the United States is unclear because of the low uptake of screening. Most AAAs are asymptomatic until they rupture (...) . Although the risk for rupture varies greatly by aneurysm size, the associated risk for death with rupture is as high as 81%.To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the effectiveness of 1-time and repeated screening for AAA, the associated harms of screening, and the benefits and harms of available treatments for small AAAs (3.0-5.4 cm in diameter) identified through screening.This recommendation applies to asymptomatic adults 50 years or older. However

2019 JAMA

126. Should This Patient Be Screened for Atrial Fibrillation?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

Should This Patient Be Screened for Atrial Fibrillation?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Atrial fibrillation (AFib) is the most common type of cardiac arrhythmia, affecting 2.7 million to 6.1 million persons in the United States. Although some persons with AFib have no symptoms, others do. For those without symptoms, AFib may be detected by 12-lead electrocardiogram (ECG), single-lead monitors (such as ambulatory blood pressure monitors and pulse oximeters (...) ), or consumer devices (such as wearable monitors and smartphones). Pulse palpation and heart auscultation also may detect AFib. In a systematic review, screening with ECG identified more new cases of AFib than no screening. Atrial fibrillation is an important cause of stroke, and without anticoagulant treatment, patients with AFib have approximately a 5-fold increased risk for stroke. The U.S. Preventive Services Task Force reviewed the benefits and harms of ECG screening for AFib in adults aged 65 years

2019 Annals of Internal Medicine

127. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. (Abstract)

Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Recommendations vary regarding the maximum age at which to stop lung cancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74 years according to the National Lung Screening Trial (NLST).To compare the cost-effectiveness of different stopping ages for lung cancer screening.By (...) using shared inputs for smoking behavior, costs, and quality of life, 4 independently developed microsimulation models evaluated the health and cost outcomes of annual lung cancer screening with low-dose computed tomography (LDCT).The NLST; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SEER (Surveillance, Epidemiology, and End Results) program; Nurses' Health Study and Health Professionals Follow-up Study; and U.S. Smoking History Generator.Current, former, and never-smokers aged

2019 Annals of Internal Medicine

128. Helping physicians fatigued by TSH Screening and Subclinical Hypothyroidism

Helping physicians fatigued by TSH Screening and Subclinical Hypothyroidism Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca December 9, 2019 (en français) Helping physicians fatigued by TSH Screening and Subclinical Hypothyroidism Clinical Question: Is there evidence for screening for thyroid function or treating subclinical hypothyroidism? Bottom Line: There is no randomized controlled trial (RCT) of screening for thyroid function [ordering thyroid stimulating hormone (TSH) in non-pregnant healthy people]. Despite approximately 20 RCTs, there are no patient-oriented benefits (like preventing cardiovascular disease

2019 Tools for Practice

129. The screening and management of newborns at risk for low blood glucose

The screening and management of newborns at risk for low blood glucose Hypoglycemia in the first hours to days after birth remains one of the most common conditions facing practitioners across Canada who care for newborns. Many cases represent normal physiologic transition to extrauterine life, but another group experiences hypoglycemia of longer duration. This statement addresses key issues for providers of neonatal care, including the definition of hypoglycemia, risk factors, screening (...) protocols, blood glucose levels requiring intervention, and managing care for this condition. Screening, monitoring, and intervention protocols have been revised to better identify, manage, and treat infants who are at risk for persistent, recurrent, or severe hypoglycemia. The role of dextrose gels in raising glucose levels or preventing more persistent hypoglycemia, and precautions to reduce risk for recurrence after leaving hospital, are also addressed. This statement differentiates between

2019 Canadian Paediatric Society

130. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care

Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Richard Birtwhistle , Kate Morissette , James A. Dickinson , Donna L. Reynolds , Marc T. Avey , Francesca Reyes Domingo , Rachel Rodin (...) of Family Medicine and Community Health Sciences (Dickinson), University of Calgary, Alta.; Dalla Lana School of Public Health and Department of Family and Community Medicine (Reynolds), University of Toronto, Ont.; Department of Psychiatry (Thombs), Jewish General Hospital and McGill University, Montréal, Que. KEY POINTS The Canadian Task Force on Preventive Health Care strongly recommends against screening for thyroid dysfunction in asymptomatic nonpregnant adults. Screening for thyroid dysfunction

2019 Canadian Task Force on Preventive Health Care

131. Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women

Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women (current immunosuppressants are listed in Table 2). Women with RA and IBD not on immunosuppressants and women with DM were considered at no increased risk compared with the general population. Screening recommendations based on these risks are summarizedinTable3. REFERENCES 1. GrulichAE,vanLeeuwenMT,FalsterMO,etal.Incidence ofcancersin peoplewithHIV/AIDScomparedwithimmunosuppressedtransplant recipients (...) . If resultofcytologyisnormalandHPVisnegative,co-testingcanbe performedevery 3 y -Iftransplantbefore theage of21y, begin screening within1 yofsexualdebut -Continue screeningthroughout lifetime (older than 65y). Discontinue screeningbasedonshareddiscussionregardingqualityand durationoflife rather thanage -Screenpatientsondialysis and posttransplantsimilarly Allogeneichematopoietic stem cell transplant -Cytologyisrecommendedifyounger than 30y -Co-testingispreferred, but cytologyisacceptableif 30yorolder -Ifusing cytologyalone, perform

2019 American Society for Clinical Pathology

132. Screening and Management of the Hyperandrogenic Adolescent

Screening and Management of the Hyperandrogenic Adolescent ACOGCOMMITTEEOPINION Number 789 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care in collaboration with committee members Jennie Yoost, MD and Ashlyn Savage, MD. Screening and Management of the Hyperandrogenic Adolescent ABSTRACT: Although androgen excess can manifest in many ways, the most common and recognizable (...) of PCOS and those of normal puberty,whichmakesthediagnosisofPCOSintheadolescentdifficult.Treatmentofacneandhirsutismshould not be withheld during the ongoing longitudinal evaluation for possible PCOS. On physical examination, body mass index, blood pressure, and signs of hyperandrogenism, such as acne and hirsutism, should be evaluated. Although guidelines differ on recommended laboratory studies, most include measurement of total testoster- one, free testosterone, or both, and screening

2019 American College of Obstetricians and Gynecologists

133. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Full Text available with Trip Pro

Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy.LungSEARCH was a national multicentre randomised trial (...) . Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were

2019 EvidenceUpdates

134. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial In the United States, more than 50% of cervical cancers are diagnosed in underscreened women. Cervical cancer screening guidelines now include primary human papillomavirus (HPV) testing as a recommended strategy. Home-based HPV self-sampling is a viable option for increasing screening compliance and effectiveness; however (...) , US data are needed to inform health care system implementation.To evaluate effectiveness of mailed HPV self-sampling kits vs usual care reminders for in-clinic screening to increase detection and treatment of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and uptake of cervical cancer screening.Randomized clinical trial conducted in Kaiser Permanente Washington, a US integrated health care delivery system. Women aged 30 to 64 years with health plan enrollment for 3 years and 5 months

2019 EvidenceUpdates

135. Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines

Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines - Crow - 2019 - Transplant International - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Original (...) Article Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Division of Dermatology, Dell Medical School, University of Texas at Austin, Austin, TX, USA Montgomery Dermatology/Lankenau Institute for Medical Research, King of Prussia, PA, USA Advanced Heart Failure Center, Sentara Heart Hospital, Norfolk, VA, USA

2019 International Society for Heart and Lung Transplantation

136. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Colorectal cancer... Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline (Published 02 October 2019) Cite (...) this as: BMJ 2019;367:l5515 Visual summary of recommendation No screening FIT Every year FIT Every two years Sigmoidoscopy Single Colonoscopy Single Favours no screening Favours screening We suggest no screening Interventions compared Recommendations Screening options Population We suggest using a tool such as the QCancer® calculator to estimate the risk of colorectal cancer for each person in the next 15 years. This calculates risk, based on: Understanding a person’s risk of cancer can help to determine

2019 BMJ Rapid Recommendations

137. Newborn screening for sickle cell disease

Newborn screening for sickle cell disease 1 Translation of Chapters 1 to 6 of the final report S18-01 Screening auf Sichelzellkrankheit (SCD) bei Neugeborenen (Version 1.0; Status: 25 July 2019 [German original], 28 November 2019 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG (...) Reports – Commission No. S18-01 Newborn screening for sickle cell disease (SCD) 1 Extract of final report S18-01 Version 1.0 Newborn screening for sickle cell disease (SCD) 25 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Newborn screening for sickle cell disease (SCD) Commissioning agency: Federal Joint Committee Commission awarded on: 28 June 2018 Internal Commission No.: S18-01

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

138. Breast screening: Fujifilm Amulet Innovality DBT system evaluation

Breast screening: Fujifilm Amulet Innovality DBT system evaluation Breast screening: Fujifilm Amulet Innovality DBT system evaluation - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Breast screening: Fujifilm (...) Amulet Innovality DBT system evaluation Practical evaluation of the Fujifilm Amulet Innovality digital breast tomosynthesis system used in the NHS breast screening programme. Published 9 December 2019 Last updated 9 December 2019 — From: Documents Ref: PHE publications gateway number GW-935 9 December 2019 Updated the executive summary on page 4. 9 December 2019 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t

2019 Public Health England

139. Breast screening: Hologic 3Dimensions in 2D mode

Breast screening: Hologic 3Dimensions in 2D mode Breast screening: Hologic 3Dimensions in 2D mode - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Breast screening: Hologic 3Dimensions in 2D mode Practical (...) evaluation of the Hologic 3Dimensions digital mammography system in 2D mode. Published 9 December 2019 From: Documents Ref: PHE publications gateway number GW-934 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document presents a practical evaluation of the Hologic 3Dimensions digital mammography system

2019 Public Health England

140. Cervical screening: programme overview

Cervical screening: programme overview Cervical screening: programme overview - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cervical screening: programme overview A description of the NHS cervical screening (...) programme, including evidence on screening and the human papillomavirus (HPV). Published 1 April 2015 Last updated 18 November 2019 — From: Contents is the process of identifying individuals who appear healthy but may be at increased risk of a disease or condition. The process is not perfect and in every screen there are a number of false positive and false negative results. NHS cervical screening programme is available to women and people with a cervix aged 25 to 64 in England. All eligible people who

2019 Public Health England